Skip to main content

Quest Diagnostics Inc(DGX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio

PR Newswire - Thu Apr 27, 2023

Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer

Haystack's highly sensitive minimal-residual disease cancer-detection technology to be combined with Quest's oncology, genomics and pathology expertise and scale, including solid tumor sequencing, convenient specimen collection and EHR connectivity

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.